[Severe psoriasis: beyond the skin, what are the risks of not treating the disease?].
Psoriasis is a systemic inflammatory disease whose cutaneous involvement is the most visible component. Treating the skin and the psychological effects is the main objective of today's treatments. However, the discovery of comorbidities and their effects on the frequently associated cardiac and cerebral vascular risk and on metabolic syndrome has led to substantial modification of patient management and to new therapeutic strategies. This review of the comorbidities associated with cutaneous psoriasis and the impacts of systemic treatments for psoriasis on these comorbidities aims to outline what the future may hold in terms of patient management.
Bessis
D
D
Service de Dermatologie, Université Montpellier I, Hôpital Saint-Eloi, 80, avenue Augustin-Fliche, 34295 Montpellier cedex 5, France. d-bessis@chu-montpellier.fr
D050197:Atherosclerosis / Q000453:epidemiology; D001327:Autoimmune Diseases / Q000453:epidemiology; D015897:Comorbidity; D003920:Diabetes Mellitus / Q000453:epidemiology; D006801:Humans; D007333:Insulin Resistance; D008659:Metabolic Diseases / Q000453:epidemiology; D009203:Myocardial Infarction / Q000453:epidemiology; D009765:Obesity / Q000453:epidemiology; D011565:Psoriasis / Q000150:complications* / Q000503:physiopathology* / Q000628:therapy*; D012307:Risk Factors